Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted drug could extend life for women with hard-to-treat breast cancer

NCT ID NCT07060807

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 13 times

Summary

This study tests a new drug, patritumab deruxtecan, against standard chemotherapy or another drug for people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if the new drug helps people live longer or keeps the cancer from growing. About 1000 participants will be randomly assigned to receive the new drug or the doctor's choice of treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has a diagnosis of hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)- invasive breast carcinoma that is either locally advanced disease not amenable to resection with curative intent (herein called unresectable) or metastatic disease not treatable with curative intent * Has centrally-confirmed HR+ and HER2- results and human epidermal growth factor receptor 3 (HER3) evaluable results from a biopsy obtained from a distant metastatic site or a locally advanced lesion on or after the most recent line of therapy (with certain exceptions) * Must have had progression or recurrence on prior cyclin-dependent kinase (CDK)4/6 inhibitor + endocrine therapy (ET) with one of the following: * Radiographic disease progression, as assessed by the investigator, on CDK4/6 inhibitor + ET as 1L for treatment of unresectable locally advanced or metastatic HR+/HER2- breast cancer. CDK4/6 inhibitor + ET must be the only line of therapy received in the advanced setting, or * Disease recurrence, either radiographic and/or confirmed histologically via biopsy as assessed by the investigator, while on adjuvant ET in combination with a CDK4/6 inhibitor OR within 24 months from the date of last dose of adjuvant CDK4/6 inhibitor * Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy * Has an Eastern Cooperative Oncology Group performance status of 0 or 1 assessed within 7 days before randomization Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has breast cancer amenable to treatment with curative intent * Is eligible to receive additional endocrine-based treatment in the advanced setting as determined by the investigator * Has a known germline breast cancer gene (BRCA) mutation (deleterious or suspected deleterious) where poly (ADP-ribose) polymerase (PARP) inhibitor(s) is a potential treatment option * Has current visceral crisis or is at risk for impending visceral crisis that has or may cause imminent organ compromise and/or other life-threatening complications * Has any of the following: a pulse oximeter reading \<92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has ≥Grade 2 peripheral neuropathy. * Has clinically significant corneal disease * Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer * Has received prior treatment with an anti-HER3 antibody and/or antibody-drug conjugate that consists of a topoisomerase I inhibitor (eg, T-DXd) or any other topoisomerase I inhibitor therapy * Has received prior systemic anticancer therapy within 4 weeks (or 5 half-lives, whichever is shorter) before randomization; participants previously treated with ET plus a CDK4/6 inhibitor may participate as long as at least 2 weeks have elapsed since the last dose of therapy was administered * Has received prior radiotherapy for non-central nervous system disease, or required corticosteroids for radiation-related toxicities, within 14 days of the first dose of study intervention * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy * Has known additional malignancy that is progressing or has required active treatment within the past 3 years * Has history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/interstitial lung disease, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening * Has severe hypersensitivity (≥Grade 3) to HER3-DXd and/or any of its excipients * Has severe hypersensitivity (≥Grade 3) to all the available TPC and/or any of their excipients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    197 sites in 26 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • ANIMI - Unidade de Tratamento Oncologico ( Site 0306)

    RECRUITING

    Lages, Santa Catarina, 88501-001, Brazil

  • Adana Medical Park Seyhan Hastanesi ( Site 2110)

    RECRUITING

    Adana, 1140, Turkey (Türkiye)

  • AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0024)

    RECRUITING

    Altamonte Springs, Florida, 32701, United States

  • Affiliated Cancer Hospital of Shandong First Medical University ( Site 3115)

    RECRUITING

    Jinan, Shandong, 250117, China

  • Aichi Cancer Center ( Site 3200)

    RECRUITING

    Nagoya, Aichi-ken, 464-8681, Japan

  • Akita University Hospital ( Site 3207)

    RECRUITING

    Akita, 010-8543, Japan

  • Anhui Provincial Cancer Hospital ( Site 3140)

    RECRUITING

    Hefei, Anhui, 230088, China

  • Ankara Bilkent Şehir Hastanesi ( Site 2105)

    COMPLETED

    Ankara, 6800, Turkey (Türkiye)

  • Aretaieio Hospital ( Site 1103)

    RECRUITING

    Athens, Attica, 11528, Greece

  • Asan Medical Center ( Site 2705)

    RECRUITING

    Seoul, 05505, South Korea

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII ( Site 1507)

    RECRUITING

    Bergamo, Lombardy, 24127, Italy

  • Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 1200)

    RECRUITING

    Kecskemét, Bács-Kiskun county, 6000, Hungary

  • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 2924)

    RECRUITING

    Dusit, Bangkok, 10300, Thailand

  • Baptist Health Hamburg ( Site 0071)

    RECRUITING

    Lexington, Kentucky, 40509, United States

  • Baptist Health Lexington ( Site 0050)

    RECRUITING

    Lexington, Kentucky, 40503, United States

  • Baskent Universitesi Adana Dr. Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 2107)

    RECRUITING

    Adana, 01120, Turkey (Türkiye)

  • Bialostockie Centrum Onkologii ( Site 1604)

    RECRUITING

    Bialystok, Podlaskie Voivodeship, 15-027, Poland

  • Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 2300)

    RECRUITING

    Blacktown, New South Wales, 2148, Australia

  • Bradfordhill ( Site 0401)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • CENTRE LEON BERARD ( Site 0900)

    RECRUITING

    Lyon, Rhone, 69008, France

  • CHRU de Brest ( Site 0904)

    RECRUITING

    Brest, Finistere, 29200, France

  • CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 1820)

    RECRUITING

    A Coruña, La Coruna, 15006, Spain

  • CIDO SpA ( Site 0408)

    RECRUITING

    Temuco, Araucania, 4810218, Chile

  • CIO - Centro de Inmuno-Oncología de Occidente ( Site 0600)

    RECRUITING

    Guadalajara, Jalisco, 44630, Mexico

  • Cancer Care Associates Of York ( Site 0063)

    RECRUITING

    York, Pennsylvania, 17403, United States

  • Cancer Hospital Chinese Academy of Medical Sciences ( Site 3100)

    ACTIVE_NOT_RECRUITING

    Beijing, Beijing Municipality, 100021, China

  • Centre Hospitalier de l'Université de Montréal ( Site 0113)

    RECRUITING

    Montreal, Quebec, H2X 3E4, Canada

  • Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen ( Site 0901)

    RECRUITING

    Rouen, Seine-Maritime, 76038, France

  • Centro Privado de RMI Rio Cuarto ( Site 0207)

    RECRUITING

    Río Cuarto, Córdoba Province, X5800ALB, Argentina

  • Centro de Investigacion Clinica de Oaxaca ( Site 0601)

    RECRUITING

    Oaxaca City, 68020, Mexico

  • Centro de Oncología de Precisión ( Site 0410)

    RECRUITING

    Santiago, Region M. de Santiago, 7560908, Chile

  • Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 1618)

    RECRUITING

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Chi-Mei Medical Center ( Site 2805)

    RECRUITING

    Tainan, 710, Taiwan

  • Chiba Cancer Center ( Site 3203)

    RECRUITING

    Chiba, 260-8717, Japan

  • Chongqing Three Gorges Central Hospital's ( Site 3128)

    RECRUITING

    Wanzhou, Chongqing Municipality, 404000, China

  • Chris O'Brien Lifehouse ( Site 2302)

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Circuit Clinical/SSM Health Dean Medical Group ( Site 0039)

    RECRUITING

    Madison, Wisconsin, 53715, United States

  • Clínica Internacional - Sede San Borja ( Site 0704)

    RECRUITING

    San Borja, Lima region, 15036, Peru

  • Clínica MEDS La Dehesa ( Site 0405)

    RECRUITING

    Santiago, Region M. de Santiago, 7691236, Chile

  • Comprehensive Hematology Oncology ( Site 0060)

    RECRUITING

    St. Petersburg, Florida, 33709, United States

  • Cuidados Oncologicos. ( Site 0605)

    RECRUITING

    Querétaro City, Querétaro, 76000, Mexico

  • Dicle Üniversitesi ( Site 2102)

    RECRUITING

    Diyarbakır, 21280, Turkey (Türkiye)

  • Ditmanson Medical Foundation Chia-Yi Christian Hospital ( Site 2806)

    RECRUITING

    Chiayi City, Chiayi, 600, Taiwan

  • European Interbalkan Medical Center-Oncology Department ( Site 1101)

    RECRUITING

    Thessaloniki, 570 01, Greece

  • FALP ( Site 0400)

    RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0502)

    RECRUITING

    Bogotá, Bogota D.C., 110131, Colombia

  • Faculty of Medicine Siriraj Hospital ( Site 2921)

    RECRUITING

    Bangkoknoi, Bangkok, 10700, Thailand

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1501)

    RECRUITING

    Milan, 20133, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1500)

    RECRUITING

    Roma, 00144, Italy

  • Fukushima Medical University Hospital ( Site 3212)

    RECRUITING

    Fukushima, 960-1295, Japan

  • Fundación Respirar ( Site 0201)

    RECRUITING

    Buenos Aires, Buenos Aires F.D., C1426AAL, Argentina

  • Gangnam Severance Hospital, Yonsei University Health System ( Site 2701)

    RECRUITING

    Gangnam-gu, Seoul, 06273, South Korea

  • Gazi University Health Research and Application Center Gazi Hospital ( Site 2101)

    RECRUITING

    Ankara, 06560, Turkey (Türkiye)

  • General Hospital of Athens "Laiko" ( Site 1105)

    RECRUITING

    Athens, Attica, 11527, Greece

  • Guangxi Medical University Affiliated Tumor Hospital ( Site 3118)

    RECRUITING

    Nanning, Guangxi, 530021, China

  • Gustave Roussy ( Site 0903)

    RECRUITING

    Villejuif, Val-de-Marne, 94800, France

  • Hacettepe Universite Hastaneleri ( Site 2100)

    RECRUITING

    Ankara, 06230, Turkey (Türkiye)

  • Hadassah Medical Center ( Site 1404)

    RECRUITING

    Jerusalem, 9112001, Israel

  • Hanoi Oncology Hospital ( Site 3030)

    RECRUITING

    Hanoi, Hanoi, 100000, Vietnam

  • Henan Cancer Hospital ( Site 3108)

    RECRUITING

    Zhengzhou, Henan, 450008, China

  • Hiroshima City Hiroshima Citizens Hospital ( Site 3214)

    RECRUITING

    Hiroshima, 730-8518, Japan

  • Hoag Memorial Hospital Presbyterian ( Site 0025)

    RECRUITING

    Newport Beach, California, 92663, United States

  • Hospital Aleman ( Site 0200)

    RECRUITING

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1118AAT, Argentina

  • Hospital Clinic de Barcelona ( Site 1821)

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital Clinico San Carlos... ( Site 1822)

    RECRUITING

    Madrid, 28040, Spain

  • Hospital Italiano de Córdoba ( Site 0206)

    RECRUITING

    Córdoba, X5004BAL, Argentina

  • Hospital Paulistano ( Site 0304)

    RECRUITING

    São Paulo, 01321-001, Brazil

  • Hospital Universitario Marques de Valdecilla ( Site 1825)

    RECRUITING

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario Ramon y Cajal ( Site 1824)

    RECRUITING

    Madrid, 28034, Spain

  • Hospital Universitario Virgen de Valme ( Site 1826)

    RECRUITING

    Seville, 41014, Spain

  • Hospital de Câncer de Recife ( Site 0302)

    RECRUITING

    Recife, Pernambuco, 50040-000, Brazil

  • Hospital do Câncer Mãe de Deus ( Site 0300)

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90470-340, Brazil

  • Hunan Cancer Hospital ( Site 3134)

    RECRUITING

    Changsha, Hunan, 410013, China

  • IMAT S.A.S ( Site 0500)

    RECRUITING

    Montería, Departamento de Córdoba, 230002, Colombia

  • IPOR Instituto Peruano de Oncología & Radioterapia ( Site 0701)

    RECRUITING

    San Isidro, Lima region, 15036, Peru

  • Institut Català d'Oncologia (ICO) - Badalona ( Site 1823)

    RECRUITING

    Badalona, Barcelona, 08916, Spain

  • Instituto Alexander Fleming ( Site 0202)

    RECRUITING

    CABA, C1426DRB, Argentina

  • Instituto Nacional De Cancerologia ( Site 0504)

    RECRUITING

    Bogotá, Bogota D.C., 111511, Colombia

  • Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 0702)

    RECRUITING

    Concepción, Departamento de Junín, 12125, Peru

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0205)

    RECRUITING

    Mar del Plata, Buenos Aires, B7600FZO, Argentina

  • Instituto de Oncologia Saint Gallen ( Site 0308)

    RECRUITING

    Santa Cruz do Sul, Rio Grande do Sul, 96830-180, Brazil

  • Instituto de Oncología de Rosario ( Site 0208)

    RECRUITING

    Rosario, Santa Fe Province, S2000KZE, Argentina

  • Istituto Europeo di Oncologia IRCCS ( Site 1508)

    RECRUITING

    Milan, Lombardy, 20141, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Clinica Sperimentale di Senologia ( Site 1506)

    RECRUITING

    Naples, 80131, Italy

  • JPS Health Network ( Site 0067)

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • Jiangmen Central Hospital ( Site 3132)

    RECRUITING

    Jiangmen, Guangdong, 529000, China

  • Jiangsu Cancer Hospital ( Site 3107)

    RECRUITING

    Nanjing, Jiangsu, 210009, China

  • Jiangsu Province Hospital ( Site 3105)

    RECRUITING

    Nanjing, Jiangsu, 210029, China

  • Jilin Cancer Hospital ( Site 3116)

    RECRUITING

    Changchun, Jilin, 132000, China

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001)

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Kansai Medical University Hospital ( Site 3213)

    RECRUITING

    Hirakata, Osaka, 573-1191, Japan

  • Kindai University Hospital ( Site 3204)

    RECRUITING

    Sakai, Osaka, 590-0197, Japan

  • Klinikum Dortmund Klinikzentrum Mitte ( Site 1005)

    RECRUITING

    Dortmund, North Rhine-Westphalia, 44137, Germany

  • Klinikum Lippe Detmold ( Site 1008)

    RECRUITING

    Detmold, North Rhine-Westphalia, 32756, Germany

  • Klinikum Mutterhaus der Borromäerinnen ( Site 1018)

    RECRUITING

    Trier, Rhineland-Palatinate, 54290, Germany

  • Koç Üniversitesi Hastanesi ( Site 2104)

    RECRUITING

    Istanbul, 34010, Turkey (Türkiye)

  • Laboratorio de Patología Clínica del Hospital Universitario "Dr. José Eleuterio González" ( Site 0604)

    RECRUITING

    Monterrey, Nuevo León, 64460, Mexico

  • Leicester Royal Infirmary ( Site 2205)

    RECRUITING

    Leicester, LE1 5WW, United Kingdom

  • Liga Norte Riograndense Contra o Câncer ( Site 0301)

    RECRUITING

    Natal, Rio Grande do Norte, 59062-000, Brazil

  • Los Angeles Hematology Oncology Medical Group ( Site 0026)

    RECRUITING

    Los Angeles, California, 90017, United States

  • MacKay Memorial Hospital ( Site 2802)

    RECRUITING

    Taipei, 10449, Taiwan

  • Maharaj Nakorn Chiang Mai Hospital ( Site 2925)

    RECRUITING

    Muang, Chiang Mai, 50200, Thailand

  • Mays Cancer Center ( Site 0049)

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Medical Oncology Hematology Consultants (MOHC) ( Site 8002)

    RECRUITING

    Newark, Delaware, 19713, United States

  • Memorial Ankara Hastanesi ( Site 2106)

    RECRUITING

    Ankara, 06520, Turkey (Türkiye)

  • Mersin Sehir Eğitim ve Araştırma Hastanesi ( Site 2103)

    RECRUITING

    Mersin, 33240, Turkey (Türkiye)

  • Mie University Hospital ( Site 3216)

    RECRUITING

    Tsu, Mie-ken, 514-8507, Japan

  • Monash Medical Centre ( Site 2301)

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • Nagoya City University Hospital ( Site 3210)

    RECRUITING

    Nagoya, Aichi-ken, 467-8602, Japan

  • Nanchang People's Hospital ( Site 3124)

    RECRUITING

    Nanchang, Jiangxi, 330025, China

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1600)

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Center Hospital ( Site 3206)

    RECRUITING

    Chūō, Tokyo, 104-0045, Japan

  • National Cheng Kung University Hospital ( Site 2804)

    RECRUITING

    Tainan, 704302, Taiwan

  • National Hospital Organization Hokkaido Cancer Center ( Site 3215)

    RECRUITING

    Sapporo, Hokkaido, 003-0804, Japan

  • National Hospital Organization Kyushu Cancer Center ( Site 3208)

    RECRUITING

    Fukuoka, 811-1395, Japan

  • National Hospital Organization Osaka National Hospital ( Site 3201)

    RECRUITING

    Osaka, 540-0006, Japan

  • National Hospital Organization Shikoku Cancer Center ( Site 3218)

    RECRUITING

    Matsuyama, Ehime, 791-0280, Japan

  • National Taiwan University Cancer Center (NTUCC) ( Site 2801)

    RECRUITING

    Taipei, 106, Taiwan

  • National Taiwan University Hospital ( Site 2800)

    RECRUITING

    Taipei, 10048, Taiwan

  • Northwest Medical Specialties, PLLC ( Site 0062)

    RECRUITING

    Tacoma, Washington, 98405, United States

  • Novant Health Cancer Institute ( Site 0019)

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Novant Health Oncology Specialists ( Site 0074)

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

  • Okayama University Hospital ( Site 3217)

    RECRUITING

    Okayama, 700-8558, Japan

  • Oncology Consultants P.A. ( Site 0061)

    RECRUITING

    Houston, Texas, 77030, United States

  • Oncosalud ( Site 0700)

    RECRUITING

    San Borja, Lima region, 15036, Peru

  • Oncovida ( Site 0402)

    RECRUITING

    Santiago, Region M. de Santiago, 7500994, Chile

  • Optum Medical Care, PC ( Site 0009)

    RECRUITING

    Westbury, New York, 11590, United States

  • Országos Onkológiai Intézet-B-Belgyógyászati Onkológiai Osztály ( Site 1201)

    RECRUITING

    Budapest, 1122, Hungary

  • Ospedale San Raffaele. ( Site 1502)

    RECRUITING

    Milan, 20132, Italy

  • Peking University People's Hospital ( Site 3138)

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

  • Presbyterian Kaseman Hospital ( Site 0072)

    RECRUITING

    Albuquerque, New Mexico, 87110, United States

  • Presbyterian Rust Jorgensen Cancer ( Site 0073)

    RECRUITING

    Rio Rancho, New Mexico, 87124, United States

  • Prince of Wales Hospital ( Site 3301)

    RECRUITING

    Hong Kong, Hong Kong

  • Princess Margaret Cancer Center ( Site 0116)

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Princess Margaret Hospital. ( Site 3302)

    RECRUITING

    Hong Kong, Hong Kong

  • Promotora Médica Las Américas S.A. ( Site 0503)

    RECRUITING

    Medellín, Antioquia, 050025, Colombia

  • Queen Mary Hospital ( Site 3300)

    RECRUITING

    Pokfulam, Hong Kong

  • Queens Hospital Cancer Center ( Site 0011)

    RECRUITING

    Jamaica, New York, 11432, United States

  • Ramathibodi Hospital. ( Site 2923)

    RECRUITING

    Ratchathewi, Bangkok, 10400, Thailand

  • Rambam Health Care Campus ( Site 1401)

    RECRUITING

    Haifa, 3109601, Israel

  • Recep Tayyip Erdogan University Training and Research Hospital ( Site 2108)

    RECRUITING

    Rize, 53020, Turkey (Türkiye)

  • Rutgers Cancer Institute of New Jersey ( Site 0033)

    RECRUITING

    New Brunswick, New Jersey, 08903, United States

  • SCRI Oncology Partners ( Site 7000)

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Saitama Medical University International Medical Center ( Site 3220)

    RECRUITING

    Hidaka, Saitama, 350-1298, Japan

  • Salve Medica sp. z o.o. sp. k. ( Site 1615)

    RECRUITING

    Lodz, Łódź Voivodeship, 91-211, Poland

  • Samsun Medical Park Hastanesi ( Site 2109)

    RECRUITING

    Samsun, 55200, Turkey (Türkiye)

  • Samsung Medical Center ( Site 2704)

    RECRUITING

    Gangnam-gu, Seoul, 06351, South Korea

  • Saskatoon Cancer Centre ( Site 0106)

    RECRUITING

    Saskatoon, Saskatchewan, S7N 4H4, Canada

  • Semmelweis Egyetem-Belgyógyászati és Hematológiai Klinika ( Site 1202)

    RECRUITING

    Budapest, 1088, Hungary

  • Seoul National University Bundang Hospital ( Site 2703)

    RECRUITING

    Seongnam, Kyonggi-do, 13620, South Korea

  • Seoul National University Hospital ( Site 2702)

    RECRUITING

    Jongno-Gu, Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System ( Site 2700)

    RECRUITING

    Seoul, 03722, South Korea

  • Shaare Zedek Medical Center ( Site 1406)

    RECRUITING

    Jerusalem, 9103102, Israel

  • Sheba Medical Center ( Site 1400)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Shenandoah Oncology ( Site 8004)

    RECRUITING

    Winchester, Virginia, 22601, United States

  • Shizuoka Cancer Center ( Site 3202)

    RECRUITING

    Sunto-gun, Shizuoka, 411-8777, Japan

  • Showa Medical University Hospital ( Site 3209)

    RECRUITING

    Shinagawa, Tokyo, 142-8666, Japan

  • Sichuan Cancer Hospital. ( Site 3110)

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • Sir Charles Gairdner Hospital ( Site 2304)

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Sir Run Run Shaw Hospital ( Site 3117)

    RECRUITING

    Hangzhou, Zhejiang, 310016, China

  • Social medical corporation Hakuaikai Sagara Hospital ( Site 3219)

    RECRUITING

    Kagoshima, 892-0833, Japan

  • Sociedad De Oncología y Hematología Del Cesar SAS ( Site 0501)

    RECRUITING

    Valledupar, Cesar Department, 200001, Colombia

  • Songklanagarind Hospital ( Site 2922)

    RECRUITING

    Hat Yai, Changwat Songkhla, 90110, Thailand

  • Southern Cancer Center (SCC) ( Site 8000)

    RECRUITING

    Daphne, Alabama, 36526, United States

  • St Bartholomew s Hospital ( Site 2200)

    RECRUITING

    London, London, City of, EC1A 7BE, United Kingdom

  • St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021)

    RECRUITING

    Grand Junction, Colorado, 81501, United States

  • Sun Yat-Sen University Cancer Center ( Site 3102)

    RECRUITING

    Guangzhou, Guangdong, 510060, China

  • Sunnybrook Research Institute ( Site 0105)

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

  • Szabolcs Szatmár Bereg Vármegyei Oktatókórház Oncoradiology ( Site 1203)

    RECRUITING

    Nyíregyháza, Szabolcs-Szatmár-Bereg, 4400, Hungary

  • Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 1614)

    RECRUITING

    Olsztyn, Warmian-Masurian Voivodeship, 10-228, Poland

  • Szpital Wojewodzki im.M.Kopernika. ( Site 1607)

    RECRUITING

    Koszalin, West Pomeranian Voivodeship, 75-581, Poland

  • Taichung Veterans General Hospital ( Site 2803)

    RECRUITING

    Taichung, 407, Taiwan

  • Taizhou Hospital of Zhejiang Province ( Site 3137)

    RECRUITING

    Linhai, Zhejiang, 317000, China

  • Tennessee Oncology ( Site 0068)

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Texas Oncology - Central/South Texas ( Site 8005)

    RECRUITING

    McAllen, Texas, 78503, United States

  • Texas Oncology - DFW ( Site 8003)

    RECRUITING

    Dallas, Texas, 75246, United States

  • Texas Oncology - Gulf Coast ( Site 8006)

    RECRUITING

    Houston, Texas, 77024, United States

  • The Alfred Hospital ( Site 2305)

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • The Christie NHS Foundation Trust ( Site 2208)

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • The First Affiliated Hospital of Chongqing Medical University ( Site 3101)

    RECRUITING

    Chongqing, Chongqing Municipality, 400016, China

  • The First Affiliated hospital of Xiamen University ( Site 3120)

    RECRUITING

    Fujian, Fujian, 361003, China

  • The Moncton Hospital ( Site 0101)

    RECRUITING

    Moncton, New Brunswick, E1C 6Z8, Canada

  • The University of Arizona Cancer Center - North Campus ( Site 0055)

    RECRUITING

    Tucson, Arizona, 85719, United States

  • Toranomon Hospital ( Site 3205)

    RECRUITING

    Minato, Tokyo, 105-8470, Japan

  • TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0020)

    RECRUITING

    Cincinnati, Ohio, 45220, United States

  • Tuen Mun Hospital ( Site 3303)

    RECRUITING

    Hong Kong, Hong Kong

  • Unidad de Mastologia Avanzada de Chihuahua S.A de C.V ( Site 0602)

    RECRUITING

    Chihuahua City, 31123, Mexico

  • Universitaetsklinikum des Saarlandes-Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedi ( Site 1003)

    RECRUITING

    Homburg, Saarland, 66424, Germany

  • University College London Hospital ( Site 2206)

    RECRUITING

    London, England, NW1 2PG, United Kingdom

  • University General Hospital of Heraklion ( Site 1102)

    RECRUITING

    Heraklion, Irakleio, 71500, Greece

  • University of New Mexico Comprehensive Cancer Center ( Site 0047)

    RECRUITING

    Albuquerque, New Mexico, 87131, United States

  • University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058)

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • Virginia Oncology Associates (VOA) ( Site 8001)

    RECRUITING

    Norfolk, Virginia, 23502, United States

  • West China Hospital of Sichuan University ( Site 3139)

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku-Oncologii, Chemioterapii ( Site 1616)

    RECRUITING

    Słupsk, Pomeranian Voivodeship, 76-200, Poland

  • Xi'an International Medical Center Hospital ( Site 3122)

    RECRUITING

    Xi'an, Shaanxi, 710100, China

  • Xiangyang Central Hospital ( Site 3123)

    RECRUITING

    Xiangyang, Hubei, 441106, China

  • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3112)

    RECRUITING

    Ürümqi, Xinjiang, 830000, China

  • Zhejiang Cancer Hospital ( Site 3109)

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.